Cargando…
Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasing...
Autores principales: | Lisette, Del Corso, Enrico, Balleari, Eleonora, Arboscello, Riccardo, Ghio, Manlio, Mencoboni, Omar, Racchi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836304/ https://www.ncbi.nlm.nih.gov/pubmed/24307957 http://dx.doi.org/10.1155/2013/520712 |
Ejemplares similares
-
SAT545 Erythropoietic Thyroid Nodule in the Setting of Myelofibrosis
por: Vasquez, Libia M, et al.
Publicado: (2023) -
Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014) -
Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
por: Di Tucci, Anna Angela, et al.
Publicado: (2007) -
Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
por: Saigo, Katsuyasu, et al.
Publicado: (2013) -
Elimination of Young Erythrocytes from Blood Circulation and Altered Erythropoietic Patterns during Paraquat Induced Anemic Phase in Mice
por: Bhardwaj, Nitin, et al.
Publicado: (2014)